Assess whether biosimilarity is analytically justified (a2324f)

Situation

A mid-size sponsor after a complete response letter cannot treat an inspector asking for batch records you cannot produce this week as color commentary on RWE protocol that may not meet regulator expectations. CMC change-control owner must close biosimilarity is analytically justified from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• The population in RWE protocol that may not meet regulator expectations is the one an inspector asking for batch records you cannot produce this week named, so Proceed under protocol follows for this Pharmacovigilance file.
• The population in RWE protocol that may not meet regulator expectations is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the pathway is the honest Pharma & Life Sciences call.
• A mid-size sponsor after a complete response letter already contained an inspector asking for batch records you cannot produce this week before RWE protocol that may not meet regulator expectations arrived; no new Pharmacovigilance path.
• Provenance on RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an inspector asking for batch records you cannot produce this week.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against an inspector asking for batch records you cannot produce this week and write the one fact that would move biosimilarity is analytically justified for CMC change-control owner.

Recommendation